Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-CD19 Monoclonal Antibody (B-Cell Depleting)

Inebilizumab (Anti-CD19 — IgG4-Related Disease)

Brand names: Uplizna

Inebilizumab is a humanised anti-CD19 monoclonal antibody given by intravenous infusion. It is used to deplete B cells in CD19-positive disease, with established use in neuromyelitis optica spectrum disorder and emerging use in other antibody-mediated conditions.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds CD19 on B cells and antibody-secreting plasmablasts, causing antibody-dependent cellular cytotoxicity and depletion of a broad range of the B-cell lineage.

Prescribing in practice

  • Screen for hepatitis B and active or latent infection before treatment, as B-cell depletion increases the risk of serious and reactivated infection.
  • Premedication with a corticosteroid, antihistamine and antipyretic is used to reduce infusion-related reactions.
  • Update vaccinations before starting where possible and avoid live vaccines during B-cell depletion.

Monitoring

Monitor immunoglobulin levels, full blood count and for signs of infection during and after the depletion period.

Counselling the patient

  • Report fever, persistent cough or any new infection promptly.
  • Tell any clinician you have received a B-cell depleting medicine, as effects persist for months.
  • Infusion reactions are most likely with the first dose; staff will monitor you closely.

Evidence & guidelines

Efficacy in neuromyelitis optica spectrum disorder was shown in the N-MOmentum trial.

Reference: Stone et al. NEJM 2023 (MITIGATE trial); FDA Approval Uplizna 2024; ACR IgG4-RD Guidelines 2021; MHRA SPC (NMOSD indication); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways